Longboard Pharmaceuticals, Inc.
DelistedCIK 1832168fmd_0S6Q4VDX50JJ1QV21NYKEZ8ZWXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 03, 2020 to Sep 30, 2024, 19 periods
Latest annual · FY2023
Millions- Operating income
- (57)
- Net income
- (54)
- Free cash flow
- (38)
Latest quarter · Q3 FY2024
Millions- Operating income
- (28)
- Net income
- (25)
Bulls and bears
Loading
News summary
An AI model writes the summary on request, from this company's recent filings only, and cites each filing it uses.
AI-written
Longboard Pharmaceuticals, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Operating income | -$56.8 million | -$44.8 million | 10-K 2024-03-12 · proof | |
| Net income | -$54.4 million | -$43.9 million | 10-K 2024-03-12 · proof | |
| Cash from operating activities | -$50.9 million | -$38.1 million | 10-K 2024-03-12 · proof | |
| Total assets | $50.7 million | $70.6 million | -28.2% | 10-K 2024-03-12 · proof |
| Total liabilities | $9.8 million | $9.1 million | +6.9% | 10-K 2024-03-12 · proof |
| Cash and cash equivalents | $14.3 million | $10.8 million | +33% | 10-K 2024-03-12 · proof |
- What was Longboard Pharmaceuticals, Inc.'s operating income in fiscal 2023?
- Longboard Pharmaceuticals, Inc. reported operating income of -$56.8 million for fiscal 2023 (the year ended Dec 31, 2023), against -$44.8 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2024. SEC
- What was Longboard Pharmaceuticals, Inc.'s net income in fiscal 2023?
- Longboard Pharmaceuticals, Inc. reported net income of -$54.4 million for fiscal 2023 (the year ended Dec 31, 2023), against -$43.9 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2024. SEC
- What was Longboard Pharmaceuticals, Inc.'s cash from operating activities in fiscal 2023?
- Longboard Pharmaceuticals, Inc. reported cash from operating activities of -$50.9 million for fiscal 2023 (the year ended Dec 31, 2023), against -$38.1 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2024. SEC
- What are Longboard Pharmaceuticals, Inc.'s total assets?
- As of Dec 31, 2023, Longboard Pharmaceuticals, Inc. reported total assets of $50.7 million, against $70.6 million a year earlier (-28.2%). Source: the 10-K filed with the SEC on Mar 12, 2024. SEC
- What are Longboard Pharmaceuticals, Inc.'s total liabilities?
- As of Dec 31, 2023, Longboard Pharmaceuticals, Inc. reported total liabilities of $9.8 million, against $9.1 million a year earlier (+6.9%). Source: the 10-K filed with the SEC on Mar 12, 2024. SEC
- What are Longboard Pharmaceuticals, Inc.'s cash and cash equivalents?
- As of Dec 31, 2023, Longboard Pharmaceuticals, Inc. reported cash and cash equivalents of $14.3 million, against $10.8 million a year earlier (+33%). Source: the 10-K filed with the SEC on Mar 12, 2024. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1832168&period_type=annual&limit=5"Information only, not investment advice.